Nonclinical Development of Biologics, Vaccines and Specialty Biologics - Plitnick, Lisa M.; Fuller, Claudette L.; (ed.) - Prospero Internet Bookshop

Nonclinical Development of Biologics, Vaccines and Specialty Biologics

 
Edition number: 2
Publisher: Academic Press
Date of Publication:
 
Normal price:

Publisher's listprice:
EUR 155.00
Estimated price in HUF:
66 076 HUF (62 930 HUF + 5% VAT)
Why estimated?
 
Your price:

52 861 (50 344 HUF + 5% VAT )
discount is: 20% (approx 13 215 HUF off)
Discount is valid until: 31 December 2024
The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
Click here to subscribe.
 
Availability:

Not yet published.
 
  Piece(s)

 
Long description:

Nonclinical Development of Biologics, Vaccines and Specialty Biologics, Second Edition, is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, vaccines, cell and gene therapies, and oncology therapeutics. Updated and revised, the new edition compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory guidelines. This book discusses the different types of biologics, as well as early characterization strategies, principles of study design, nonclinical pharmacokinetics and pharmacodynamics, nonclinical assays, and regulatory guidelines. A coedited book with chapters authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late-stage biologics.

Table of Contents:

Preface Section I:?Development of Biopharmaceuticals 1. Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development 2. Nonclinical Development of Monovalent and Polyvalent Biopharmaceuticals 3. Regulatory Guidelines and their Application in the Nonclinical Evaluation of Biological Medicines 4. Early De-risking Strategy for Novel Biotherapeutics 5. Pharmacokinetics, Pharmacodynamics, and Bioanalytics Section II:?Vaccines 6. ?Introduction to Vaccines and Adjuvants 7. Global Regulatory Guidelines for Vaccines 8. Special Considerations for the Nonclinical Safety Assessment of Vaccines Section III:?Specialty Biologics and Indications 9. Gene Therapy 10. Cell Therapy 11. Biological Therapies for Cancer 12. Considerations in the Development of Pluripotent Stem Cell-based Therapies